There is described a new polymorphic form of 4-(7-Hydroxy-2-isopropyl-4-oxo-4H-quinazolin- 3-yl)-benzonitrile having structural formula I(B) and to a method of preparing it. There is further a process or method for the manufacture of a pharmaceutically active quinazolinone compounds of the formula (I), wherein the symbols have the meanings given in the description, said process comprising reacting a compound of the formula (II), wherein R* is R*-C(=O)- wherein R* is independently selected from the group of meanings of R as defined for a compound of the formula (I) so that R* and R are identical to or different from each other, or R*is especially H, and R and R, R and R are as defined for a compound of the formula (I), or a salt thereof, under simultaneous or sequential condensation and cyclisation conditions with an aniline compound of the formula (III), wherein R and m are as defined for a compound of the formula (I). Further reactions and related embodiments are also claimed and disclosed.
